申请人:Rutherford L. Jennifer
公开号:US20060030714A1
公开(公告)日:2006-02-09
This invention relates to a new process for the preparation of novel substituted haloarene compounds of the formula I or IV:
respectively, wherein R
1
, R
2
, R
3
, R
4
, R
5
, X, and Y are as defined herein, that comprises a novel and efficient selective mono-lithiation of a dihaloarene of the formula II or V:
respectively, by an organo-lithium compound in the presence of a carbonyl reactant of the formula III:
wherein R
1
and R
2
are as defined herein. In the process of the instant invention, the newly formed lithiated haloarene is sequentially quenched in situ by the carbonyl reactant to form said substituted haloarene. The process is suitable for batch or continuous flow systems. The substituted haloarenes produced by the process of the present invention are useful intermediates in the preparation of N-aryl or N-heteroaryl substituted pharmaceutically active compounds that include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT
1
) receptors useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT
1
agonist or antagonist is indicated.
这项发明涉及一种新的制备式I或IV的新颖取代卤代芳烃化合物的过程:其中R1、R2、R3、R4、R5、X和Y如本文所定义,该过程包括一种新颖且高效的选择性对二卤代芳烃式II或V进行单锂化的步骤,通过在碳酰基试剂式III存在下使用有机锂化合物,其中R1和R2如本文所定义。在本发明的过程中,新形成的锂化卤代芳烃被碳酰基试剂原位顺序熄灭以形成所述的取代卤代芳烃。该过程适用于批处理或连续流系统。通过本发明的过程生产的取代卤代芳烃是制备N-芳基或N-杂环芳基取代的药用活性化合物的有用中间体,包括选择性5-羟色胺1(5-HT1)受体的拮抗剂、逆向激动剂和部分激动剂,用于治疗或预防抑郁症、焦虑症、强迫症(OCD)和其他需要5-HT1激动剂或拮抗剂的疾病。